Dota 2: Talon makes quick work of Boom, joins Aurora in $1-M PGL Wallachia S3 | ABS-CBN

ADVERTISEMENT

dpo-dps-seal
Welcome, Kapamilya! We use cookies to improve your browsing experience. Continuing to use this site means you agree to our use of cookies. Tell me more!

Dota 2: Talon makes quick work of Boom, joins Aurora in $1-M PGL Wallachia S3

Kennedy Caacbay,

ABS-CBN News

Clipboard

Talon Esports support player Carlo "Kuku" Palad. Photo from Talon Esports/FacebookTalon Esports support player Carlo "Kuku" Palad. Photo from Talon Esports/Facebook

MANILA, Philippines – Philippines-based Dota 2 organization Talon Esports has made it to the PGL Wallachia Season 3, a $1-million tournament in Bucharest.

This, as Carlo "Kuku" Palad, John "Natsumi" Vargas, and the rest of the team made fast work of Boom Esports, the squad of fellow Pinoys Timothy "TIMS" Randrup, Mc Nicholson "Mac" Villanueva, and Jaunuel "Jaunuel" Arcilla, 3-0, in the grand finals of the Southeast Asia closed qualifiers, Wednesday.

This was a contrasting result the last time the two squads faced each other, as Boom was triumphant against Talon in the regional qualifiers of DreamLeague Season 25.

Talon made sure to exact its revenge, as Kuku and Natsumi got the job done this time around.

ADVERTISEMENT

Leading by a massive amount of gold and momentum, Talon was patient in closing out the series in Game 3 and waited for its timings and the right time to push, despite Indonesian Rafli "Mikoto" Fathur Rahman's Sniper dominating the whole game.

The team finally clinched the spot after a successful skirmish at the top lane, wiping out the Boom heroes en route to the "good game" calls at the 46-minute mark.

They will join Aurora Gaming, the home of Abed "Abed" Yusop and Jinn Marrey "Palos" Lamatao, as they were directly invited to the tournament.

The Bucharest-based PGL Wallachia takes place from March 8 to 16. A whooping $300,000 awaits the grand champions, gaining the lion's share of the million-dollar esports contest.

ADVERTISEMENT

ADVERTISEMENT

It looks like you’re using an ad blocker

Our website is made possible by displaying online advertisements to our visitors. Please consider supporting us by disabling your ad blocker on our website.

Our website is made possible by displaying online advertisements to our visitors. Please consider supporting us by disabling your ad blocker on our website.